Nuvectis Pharma, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The unaudited statements are prepared under U.S. GAAP. Nuvectis is a clinical-stage oncology biopharmaceutical company; it has no approved products and has generated no product revenue.
Key financial results
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0; no product sales |
| Research and development expense | $2.367 million | $1.805 million; up $562,000 |
| General and administrative expense | $1.734 million | $1.140 million; up $594,000 |
| Operating loss | $4.101 million | $2.945 million |
| Net loss | $4.049 million | $2.943 million |
| Basic and diluted loss per share | $0.27 | $0.32; weighted-average shares rose to 14.72 million from 9.16 million |
| Net cash used in operating activities | $4.777 million | $3.076 million |
| Cash and cash equivalents at period end | $15.468 million | $19.993 million at December 31, 2022 |
All dollar amounts in the table are USD. There is no meaningful revenue or profit margin because the company has no product revenue and is operating at a loss. Finance income was $52,000, versus $2,000 in Q1 2022.
Balance sheet and liquidity
- At March 31, 2023, total assets were $16.208 million, current liabilities were $3.934 million, and stockholders’ equity was $12.274 million. The filing reports no debt.
- Cash declined $4.525 million during the quarter. Operating activities used $4.777 million; financing activities provided $252,000, principally from warrant and preferred investment option exercises, net of issuance costs. Investing cash flows were zero.
- Management said existing cash was expected to fund planned operations for at least 12 months following issuance of the financial statements. It also stated that additional capital will be required to complete clinical development and pursue regulatory and marketing approvals; financing may not be available on acceptable terms.
- A March 2023 shelf registration permits offerings of up to $150 million, including an at-the-market program of up to $40 million. No ATM shares had been sold as of March 31, 2023.
Changes, outlook, and risks
- Operating expenses increased $1.156 million year over year, and net loss increased $1.106 million. R&D growth reflected higher employee compensation, clinical and manufacturing costs, partly offset by lower license fees and professional services. G&A growth primarily reflected compensation, professional services, insurance, and public-company costs.
- Stock-based compensation was $1.402 million, compared with $156,000 in Q1 2022. Management expects R&D and G&A expenses to increase as development advances and the company expands operations.
- NXP800 is being studied in a Phase 1 trial. Its Phase 1b expansion for platinum-resistant, ARID1a-mutated ovarian carcinoma began in April 2023, after quarter-end; the program has FDA Fast Track Designation. NXP900’s IND was pending, with IND-enabling work ongoing.
- License agreements include contingent development, regulatory and commercial milestones and tiered royalties. Disclosed potential NXP800 and NXP900 milestone obligations are substantial; most contingent amounts were not accrued because the triggering events are uncertain. The company also disclosed an accrued $0.5 million UoE anniversary milestone.
- The filing warns that inability to raise additional capital could require delayed, reduced, or discontinued development or other operations. It reports no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Cash runway assumptions and the pace of cash use relative to management’s stated 12-month funding estimate.
- Clinical progress, safety and efficacy findings for NXP800, and timing and regulatory status of the NXP900 IND.
- Whether the company raises capital through the shelf or ATM, and the potential dilution and offering costs.
- Timing and conditions of license-related milestones, research commitments, and royalties.
- Share-based compensation and equity awards, including their effect on reported expenses and future share dilution.